GEO Publications
Handout
NAR 2024 (latest)
NAR 2002 (original)
All publications
FAQ
MIAME
Email GEO
NCBI
>
GEO
>
Accession Display
Not logged in |
Login
GEO help:
Mouse over screen elements for information.
Scope:
Self
Platform
Samples
Series
Family
Format:
HTML
SOFT
MINiML
Amount:
Brief
Quick
GEO accession:
Sample GSM102231
Query DataSets for GSM102231
Status
Public on Mar 30, 2006
Title
LS-116
Sample type
RNA
Source name
lung
Organism
Homo sapiens
Characteristics
Cancer
Extracted molecule
total RNA
Extraction protocol
Total RNA was isolated from lung squamous cell carcinoma samples according to Standard Trizol protocol.
Label
biotin
Label protocol
Approximately 5 µg of total RNA was processed to produce biotinylated cRNA targets.
Hybridization protocol
standard Affymetrix procedures
Scan protocol
standard Affymetrix procedures
Description
lung squamous carcinoma
Data processing
Affymetrix Microarray Suite version 5.0
Submission date
Mar 29, 2006
Last update date
Mar 29, 2006
Contact name
Jack Yu
E-mail(s)
[email protected]
Phone
858-320-3362
Fax
858-784-3182
Organization name
Veridex, LLC
Street address
3210 Merryfield Row
City
San Diego
State/province
CA
ZIP/Postal code
92121
Country
USA
Platform ID
GPL96
Series (1)
GSE4573
Gene expression signatures for predicting prognosis of squamous cell lung carcinomas
Data table header descriptions
ID_REF
VALUE
MAS5-calculated Signal intensity after global scaling the average intensity to 600.
Data table
ID_REF
VALUE
AFFX-BioB-5_at
315.3
AFFX-BioB-M_at
367.6
AFFX-BioB-3_at
144.5
AFFX-BioC-5_at
922.1
AFFX-BioC-3_at
682.4
AFFX-BioDn-5_at
1057.8
AFFX-BioDn-3_at
5350.2
AFFX-CreX-5_at
7754.4
AFFX-CreX-3_at
12002.6
AFFX-DapX-5_at
34.9
AFFX-DapX-M_at
73.1
AFFX-DapX-3_at
14.3
AFFX-LysX-5_at
47.7
AFFX-LysX-M_at
92.5
AFFX-LysX-3_at
42.2
AFFX-PheX-5_at
10.9
AFFX-PheX-M_at
16.7
AFFX-PheX-3_at
82.3
AFFX-ThrX-5_at
19.2
AFFX-ThrX-M_at
74.8
Total number of rows:
22283
Table truncated, full table size
362 Kbytes
.
Supplementary data files not provided
|
NLM
|
NIH
|
GEO Help
|
Disclaimer
|
Accessibility
|